Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: State-of-art in 2013

This analytical paper presents the modern evidence on the dual antiplatelet therapy in ST-elevation myocardial infarction. A possible replacement of one dual therapy components – clopidogrel – with newer, more effective agents, such as ticagrelor and prasugrel, is discussed. For each of the latter medications, the existing evidence base is presented, together with the results of the studies comparing clopidogrel to ticagrelor and prasugrel. It is emphasized that only ticagrelor could potentially replace clopidogrel, and only as a part of the strategy based on primary percutaneous coronary intervention. For other strategies, such as thrombolytic therapy, pharmacoinvasive approach, and impossibility of reperfusion, clopidogrel remains a nonreplaceable element of the dual antiplatelet treatment in patients with ST-elevation myocardial infarction. © 2013, Silicea-Poligraf. All rights reserved.

Авторы
Редакторы
-
Издательство
Silicea-Poligraf
Номер выпуска
1
Язык
Русский
Страницы
104-112
Статус
Опубликовано
Подразделение
-
DOI
-
Номер
-
Том
99
Год
2013
Организации
  • 1 O. M. Filatov City Clinical Hospital No. 15, Russian University of People’s Friendship, Moscow, Russian Federation
Ключевые слова
Clopidogrel; Dual antiplatelet therapy; Myocardial infarction; Prasugrel; Ticagrelor
Дата создания
19.10.2018
Дата изменения
19.10.2018
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/2139/